LIVIVO - Search results -

Search results

Result 1 - 10 of total 181

Search options

Article ; Online: [No title information]

Grove, Erik Lerkevang

2022 Volume 184, Issue 20

Title translation	Perioperativ håndtering af orale antikoagulantia: altid omtanke, men sjældent heparin.
MeSH term(s)	Anticoagulants ; Heparin ; Heparin, Low-Molecular-Weight ; Humans
Chemical Substances	Anticoagulants ; Heparin, Low-Molecular-Weight ; Heparin (9005-49-6)
Language	Danish
Publishing date	2022-05-17
Publishing country	Denmark
Document type	Journal Article ; Comment
ZDB-ID	124102-3
ISSN	1603-6824 ; 0041-5782
ISSN (online)	1603-6824
ISSN	0041-5782
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 302: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Ua VI Zs.6/30: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Large atrial mass in a patient with Crohn's disease: organised thrombus mimicking a myxoma.

Grove, Erik Lerkevang

BMJ case reports

2017 Volume 2017

MeSH term(s)	Adult ; Azathioprine/therapeutic use ; Coronary Thrombosis/complications ; Coronary Thrombosis/diagnostic imaging ; Coronary Thrombosis/surgery ; Crohn Disease/complications ; Crohn Disease/drug therapy ; Diagnosis, Differential ; Echocardiography, Transesophageal/methods ; Female ; Gastrointestinal Agents ; Heart Atria/diagnostic imaging ; Heart Atria/surgery ; Humans ; Immunosuppressive Agents ; Incidental Findings ; Infliximab/therapeutic use ; Myxoma ; Tomography, X-Ray Computed/methods
Chemical Substances	Gastrointestinal Agents ; Immunosuppressive Agents ; Infliximab (B72HH48FLU) ; Azathioprine (MRK240IY2L)
Language	English
Publishing date	2017-08-22
Publishing country	England
Document type	Case Reports ; Journal Article
ISSN	1757-790X
ISSN (online)	1757-790X
DOI	10.1136/bcr-2017-222044
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants.

Hellfritzsch, Maja / Henriksen, Jakob Nørgaard / Holt, Marianne Ingerslev / Grove, Erik Lerkevang

Seminars in thrombosis and hemostasis

2023 Volume 50, Issue 3, Page(s) 489–498

Abstract: Venous thromboembolism (VTE) is a frequent complication of cancer, and management of cancer-associated thrombosis (CAT) is challenging due to increased risks of bleeding and recurrent VTE. Recent trials have shown an acceptable efficacy and safety of ... ...

Abstract	Venous thromboembolism (VTE) is a frequent complication of cancer, and management of cancer-associated thrombosis (CAT) is challenging due to increased risks of bleeding and recurrent VTE. Recent trials have shown an acceptable efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of CAT compared to low-molecular weight heparin. Although DOACs provide an effective and convenient treatment option in CAT, the need to assess the risk of drug-drug interactions (DDI) with antineoplastic therapies poses a barrier to their use in clinical practice. With the aim of supporting the assessment of CAT patients for treatment with DOAC, this review provides a comprehensive overview of the compatibility of antineoplastic therapies with the individual DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban). Using several data sources, we characterized 100 widely used antineoplastic agents with regard to their effect on p-glycoprotein and cytochrome P450, both important in the transport and elimination of DOACs. This enabled us to evaluate 400 "DOAC-antineoplastic agent"-pairs regarding their likelihood to interact (unlikely, potential, or likely), ultimately leading to clinical recommendations on the appropriateness of concomitant use for each pair. A potential or likely DDI was identified for 12% of the evaluated pairs. For nearly all antineoplastic agents, at least one DOAC was considered compatible.
MeSH term(s)	Humans ; Venous Thromboembolism/etiology ; Venous Thromboembolism/complications ; Anticoagulants/therapeutic use ; Dabigatran/therapeutic use ; Rivaroxaban/therapeutic use ; Neoplasms/complications ; Neoplasms/drug therapy ; Antineoplastic Agents/adverse effects ; Drug Interactions ; Administration, Oral
Chemical Substances	Anticoagulants ; Dabigatran (I0VM4M70GC) ; Rivaroxaban (9NDF7JZ4M3) ; Antineoplastic Agents
Language	English
Publishing date	2023-02-02
Publishing country	United States
Document type	Review ; Journal Article
ZDB-ID	196901-8
ISSN	1098-9064 ; 0094-6176
ISSN (online)	1098-9064
ISSN	0094-6176
DOI	10.1055/s-0043-1762596
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1259: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Contemporary Clinical Use of Aspirin: Mechanisms of Action, Current Concepts, Unresolved Questions, and Future Perspectives.

Christiansen, Mikael / Grove, Erik Lerkevang / Hvas, Anne-Mette

Seminars in thrombosis and hemostasis

2021 Volume 47, Issue 7, Page(s) 800–814

Abstract: The ability of aspirin to inhibit platelet aggregation has positioned this agent within the most frequently used drugs worldwide. The aim of this article is to review the contemporary clinical use of aspirin and also to discuss unresolved issues not yet ... ...

Abstract	The ability of aspirin to inhibit platelet aggregation has positioned this agent within the most frequently used drugs worldwide. The aim of this article is to review the contemporary clinical use of aspirin and also to discuss unresolved issues not yet translated into clinical practice. Results from several clinical trials have led to strong guideline recommendations for aspirin use in the acute management and secondary prevention of cardiovascular disease. On the contrary, guidelines regarding aspirin use as primary prevention of cardiovascular disease are almost conservative, supported by recent trials reporting that the bleeding risk outweighs the potential benefits in most patients. In pregnancy, aspirin has proved efficient in preventing preeclampsia and small-for-gestational-age births in women at high risk, and is hence widely recommended in clinical guidelines. Despite the vast amount of clinical data on aspirin, several unresolved questions remain. Randomized trials have reported that aspirin reduces the risk of recurrent venous thromboembolism, but the clinical relevance remains limited, because direct oral anticoagulants are more effective. Laboratory studies suggest that a twice-daily dosing regimen or evening intake may lead to more efficient platelet inhibition, and the potential clinical benefit of such strategies is currently being explored in ongoing clinical trials. Enteric-coated formulations of aspirin are frequently used, but it remains unclear if they are safer and as efficient as plain aspirin. In the future, aspirin use after percutaneous coronary interventions might not be mandatory in patients who also need anticoagulant therapy, as several trials support shorter aspirin duration strategies. On the other hand, new treatment indications for aspirin will likely arise, as there is growing evidence that aspirin may reduce the risk of colorectal cancer and other types of cancer.
MeSH term(s)	Anticoagulants ; Aspirin/therapeutic use ; Clinical Trials as Topic ; Female ; Humans ; Platelet Aggregation ; Platelet Aggregation Inhibitors/therapeutic use ; Pregnancy ; Venous Thromboembolism
Chemical Substances	Anticoagulants ; Platelet Aggregation Inhibitors ; Aspirin (R16CO5Y76E)
Language	English
Publishing date	2021-06-15
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	196901-8
ISSN	1098-9064 ; 0094-6176
ISSN (online)	1098-9064
ISSN	0094-6176
DOI	10.1055/s-0041-1726096
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1259: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A 19-Year-Old Man with a History of Recreational Inhalation of Nitrous Oxide with Severe Peripheral Neuropathy and Central Pulmonary Embolism.

Pedersen, Oliver Buchhave / Hvas, Anne-Mette / Grove, Erik Lerkevang

The American journal of case reports

2021 Volume 22, Page(s) e931936

Abstract: BACKGROUND Recreational use of nitrous oxide (laughing gas) is a growing phenomenon among young people due to easy accessibility and a presumed innocent effect. However, complications have been reported, especially following high and long-term use, ... ...

Abstract	BACKGROUND Recreational use of nitrous oxide (laughing gas) is a growing phenomenon among young people due to easy accessibility and a presumed innocent effect. However, complications have been reported, especially following high and long-term use, including nerve damage, spontaneous pneumo-mediastinum, myocardial infarction, and macrocytic anemia. CASE REPORT We report a case of a 19-year-old previously healthy man with occasional recreational use of nitrous oxide of up to 10 times within recent months, who presented with severe peripheral neuropathy. Laboratory examination revealed severely elevated homocysteine values of 92 µmol/L (reference range, <10 µmol/L), strongly elevated methylmalonic acid level of >10 µmol/L (range, 0.1-0.4 µmol/L), vitamin B₁₂ level of 234 pmol/L (range, 200-600 pmol/L), hemoglobin level of 9.3 mmol/L (range, 8.3-10.5 mmol/L), platelets of 384×10⁹/L (range, 145-350×10⁹/L), and leucocytes of 6.2×10⁹/L (range, 3.5-10.0×10⁹/L). Nitrous oxide can result in vitamin B₁₂ inactivation and nerve damage due to lack of myelination. During hospitalization, the patient had a bilateral central pulmonary embolism, probably caused by a combination of nitrous oxide abuse and some extent of immobilization. After 6 months of nitrous oxide cessation and treatment with B vitamins, the patient experienced almost no residual symptoms, and homocysteine and methylmalonic acid levels normalized. CONCLUSIONS Our case shows that even moderate recreational use of nitrous oxide can lead to severe peripheral neuropathy as well as increase the risk of thromboembolic complications. Especially young and previously healthy individuals presenting with unexplained neuropathy or thromboembolic events should therefore be asked about possible use of nitrous oxide.
MeSH term(s)	Adolescent ; Adult ; Humans ; Male ; Nitrous Oxide/adverse effects ; Peripheral Nervous System Diseases ; Pulmonary Embolism/chemically induced ; Vitamin B 12 ; Vitamin B 12 Deficiency/chemically induced ; Vitamin B 12 Deficiency/complications ; Young Adult
Chemical Substances	Nitrous Oxide (K50XQU1029) ; Vitamin B 12 (P6YC3EG204)
Language	English
Publishing date	2021-08-11
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2517183-5
ISSN	1941-5923 ; 1941-5923
ISSN (online)	1941-5923
ISSN	1941-5923
DOI	10.12659/AJCR.931936
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases.

Kelddal, Sarah / Hvas, Anne-Mette / Grove, Erik Lerkevang / Birn, Henrik

BMC nephrology

2022 Volume 23, Issue 1, Page(s) 305

Abstract: Background: Nephrotic syndrome (NS) is associated with increased risk of thromboembolic events (TE) adding to the morbidity and mortality. International guidelines recommend prophylactic anticoagulation in patients with NS and high risk of TE, but no ... ...

Abstract	Background: Nephrotic syndrome (NS) is associated with increased risk of thromboembolic events (TE) adding to the morbidity and mortality. International guidelines recommend prophylactic anticoagulation in patients with NS and high risk of TE, but no studies have identified the optimal type of anticoagulation in NS. We aimed to assess the effectiveness and safety of direct oral anticoagulant (DOAC) by analyzing the thromboembolic and bleeding events in NS patients prescribed DOAC as primary prophylaxis to prevent TE or as treatment for TE occurring in relation to NS. Methods: We performed a single-center, retrospective study including patients with NS, a plasma albumin less than 25 g/L and prophylactic anticoagulation treatment with DOAC at the Department of Renal Medicine at Aarhus University Hospital, Denmark from July 2016 to June 2021. Patients treated with DOAC as thromboprophylaxis for other indications than NS were excluded. Baseline characteristics and outcomes, including TE, bleeding and other adverse effects associated with DOAC were obtained from medical records. Results: We identified 268 patients treated with DOAC of which 21 patients with NS were included in the study. Nineteen patients were prescribed DOAC as thromboprophylaxis and two patients received DOAC due to previous TE, which was considered associated with the NS. The type of DOAC prescribed was apixaban (n = 10) and rivaroxaban (n = 11). No patients experienced TE during DOAC treatment, while five patients had a minor bleeding episode. Patients who experienced bleeding episodes were older (median 62 vs 51 years), more often female (80%) and had been on DOAC for a longer period (204 days vs 47 days). Neither the HAS-BLED score nor GN-risk-score predicted the risk of minor bleedings in this population. Conclusions: In this case series, no new TE and only minor bleeding complications were observed among adult NS patients treated with DOAC.
MeSH term(s)	Administration, Oral ; Adult ; Anticoagulants/adverse effects ; Atrial Fibrillation/complications ; Female ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Nephrotic Syndrome/chemically induced ; Nephrotic Syndrome/complications ; Nephrotic Syndrome/drug therapy ; Retrospective Studies ; Venous Thromboembolism/chemically induced ; Venous Thromboembolism/complications ; Venous Thromboembolism/drug therapy
Chemical Substances	Anticoagulants
Language	English
Publishing date	2022-09-05
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2041348-8
ISSN	1471-2369 ; 1471-2369
ISSN (online)	1471-2369
ISSN	1471-2369
DOI	10.1186/s12882-022-02929-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Hudnekrose og følgevirkninger efter utilsigtet subkutan indgift af amiodaron.

Grove, Erik Lerkevang

Ugeskrift for laeger

2015 Volume 177, Issue 24

Title translation	Skin necrosis and consequences of accidental subcutaneous administration of amiodarone.
MeSH term(s)	Aged ; Amiodarone/administration & dosage ; Amiodarone/adverse effects ; Anti-Arrhythmia Agents/administration & dosage ; Anti-Arrhythmia Agents/adverse effects ; Drug Eruptions/etiology ; Hand/pathology ; Humans ; Male ; Necrosis/chemically induced ; Skin/pathology
Chemical Substances	Anti-Arrhythmia Agents ; Amiodarone (N3RQ532IUT)
Language	Danish
Publishing date	2015-06-02
Publishing country	Denmark
Document type	Case Reports
ZDB-ID	124102-3
ISSN	1603-6824 ; 0041-5782
ISSN (online)	1603-6824
ISSN	0041-5782
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 302: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Ua VI Zs.6/30: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Antithrombotic treatment for chronic coronary syndrome: Evidence and future perspectives.

Kulasingam, Archana / Pareek, Manan / Gragnano, Felice / Würtz, Morten / Pryds, Kasper / Calabrò, Paolo / Grove, Erik Lerkevang

Cardiology

2024

Abstract: Background The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary ... ...

Abstract	Background The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with e.g., concomitant atrial fibrillation or venous thromboembolism. Key messages This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.
Language	English
Publishing date	2024-02-14
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	80092-2
ISSN	1421-9751 ; 0008-6312
ISSN (online)	1421-9751
ISSN	0008-6312
DOI	10.1159/000537706
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui IV Zs.31: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immature platelets and cardiovascular events in patients with stable coronary artery disease.

Pedersen, Oliver Buchhave / Larsen, Sanne Bøjet / Kristensen, Steen Dalby / Hvas, Anne-Mette / Grove, Erik Lerkevang

Platelets

2023 Volume 34, Issue 1, Page(s) 2217960

Abstract: Many patients with coronary artery disease (CAD) have reduced the effect of aspirin, which may partly be explained by immature platelets. We aimed to investigate whether immature platelet markers can predict cardiovascular events in a large cohort of ... ...

Abstract	Many patients with coronary artery disease (CAD) have reduced the effect of aspirin, which may partly be explained by immature platelets. We aimed to investigate whether immature platelet markers can predict cardiovascular events in a large cohort of stable CAD patients. A total of 900 stable CAD patients were included and followed for a median of 3 years. We measured markers of immature platelets (platelet count, immature platelet count, immature platelet fraction, mean platelet volume, platelet distribution width, platelet mass, and thrombopoietin) using automated flow cytometry and studied their relation to cardiovascular events. Our primary endpoint was a composite of acute myocardial infarction (MI), ischemic stroke, and cardiovascular death. A composite of MI, ischemic stroke, stent thrombosis and all-cause mortality was analyzed as a secondary endpoint. We found no difference in immature platelet markers between CAD patients with or without cardiovascular events. Regression analysis using hazards rates showed that markers of immature platelets did not have any predictive value for endpoints (p-values >.05). Markers of immature platelets did not predict future cardiovascular events during a 3-year follow-up period in CAD patients. This suggests that immature platelets measured in a stable phase does not have a major role in predicting future cardiovascular events.
MeSH term(s)	Humans ; Coronary Artery Disease/complications ; Blood Platelets ; Myocardial Infarction/complications ; Aspirin/adverse effects ; Ischemic Stroke/complications ; Platelet Aggregation Inhibitors/adverse effects
Chemical Substances	Aspirin (R16CO5Y76E) ; Platelet Aggregation Inhibitors
Language	English
Publishing date	2023-05-25
Publishing country	England
Document type	Journal Article
ZDB-ID	1034283-7
ISSN	1369-1635 ; 0953-7104
ISSN (online)	1369-1635
ISSN	0953-7104
DOI	10.1080/09537104.2023.2217960
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2888: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Performance-based outcome measures for assessing physical capacity in patients with pulmonary embolism: A scoping review.

Caspersen, Christina Krogner / Ingemann-Molden, Stian / Grove, Erik Lerkevang / Højen, Anette Arbjerg / Andreasen, Jane / Klok, Frederikus A / Rolving, Nanna

Thrombosis research

2024 Volume 235, Page(s) 52–67

Abstract: Introduction: Up to 50 % of patients surviving a pulmonary embolism (PE) report persisting shortness of breath, reduced physical capacity and psychological distress. As the PE population is heterogeneous compared to other cardiovascular patient groups, ... ...

Abstract	Introduction: Up to 50 % of patients surviving a pulmonary embolism (PE) report persisting shortness of breath, reduced physical capacity and psychological distress. As the PE population is heterogeneous compared to other cardiovascular patient groups, outcome measures for assessing physical capacity traditionally used in cardiac populations may not be reliable for the PE population as a whole. This scoping review aims to 1) map performance-based outcome measures (PBOMs) used for assessing physical capacity in PE research, and 2) to report the psychometric properties of the identified PBOMs in a PE population. Methods: The review was conducted according to the Joanna Briggs Institute framework for scoping reviews and reported according to the PRISMA-Extension for Scoping Reviews guideline. Results: The systematic search of five databases identified 4585 studies, of which 243 studies met the inclusion criteria. Of these, 185 studies focused on a subgroup of patients with chronic thromboembolic pulmonary hypertension. Ten different PBOMs were identified in the included studies. The 6-minute walk test (6MWT) and cardiopulmonary exercise test (CPET) were the most commonly used, followed by the (Modified) Bruce protocol and Incremental Shuttle Walk test. No studies reported psychometric properties of any of the identified PBOMs in a PE population. Conclusions: Publication of studies measuring physical capacity within PE populations has increased significantly over the past 5-10 years. Still, not one study was identified, reporting the validity, reliability, or responsiveness for any of the identified PBOMs in a PE population. This should be a priority for future research in the field.
MeSH term(s)	Humans ; Reproducibility of Results ; Exercise Test ; Pulmonary Embolism/diagnosis ; Psychometrics ; Outcome Assessment, Health Care
Language	English
Publishing date	2024-01-15
Publishing country	United States
Document type	Systematic Review ; Journal Article ; Review
ZDB-ID	121852-9
ISSN	1879-2472 ; 0049-3848
ISSN (online)	1879-2472
ISSN	0049-3848
DOI	10.1016/j.thromres.2024.01.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 863: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito